JP2013528206A - 結晶形態のサリドマイド及びその調製方法 - Google Patents

結晶形態のサリドマイド及びその調製方法 Download PDF

Info

Publication number
JP2013528206A
JP2013528206A JP2013513760A JP2013513760A JP2013528206A JP 2013528206 A JP2013528206 A JP 2013528206A JP 2013513760 A JP2013513760 A JP 2013513760A JP 2013513760 A JP2013513760 A JP 2013513760A JP 2013528206 A JP2013528206 A JP 2013528206A
Authority
JP
Japan
Prior art keywords
thalidomide
crystalline
type
anhydrous crystalline
anhydrous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013513760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528206A5 (https=
Inventor
ビナヤク， ゴヴィンド ゴレ，
ヴィナイ， クマール シュクラ，
マドゥカル パティル，
サンディープ メクデ，
Original Assignee
ジェネリクス・［ユーケー］・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネリクス・［ユーケー］・リミテッド filed Critical ジェネリクス・［ユーケー］・リミテッド
Publication of JP2013528206A publication Critical patent/JP2013528206A/ja
Publication of JP2013528206A5 publication Critical patent/JP2013528206A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013513760A 2010-06-09 2011-06-09 結晶形態のサリドマイド及びその調製方法 Pending JP2013528206A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1758MU2010 2010-06-09
IN1758/MUM/2010 2010-06-09
PCT/GB2011/051078 WO2011154739A1 (en) 2010-06-09 2011-06-09 Crystalline forms of thalidomide and processes for their preparation

Publications (2)

Publication Number Publication Date
JP2013528206A true JP2013528206A (ja) 2013-07-08
JP2013528206A5 JP2013528206A5 (https=) 2014-07-24

Family

ID=44384914

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513760A Pending JP2013528206A (ja) 2010-06-09 2011-06-09 結晶形態のサリドマイド及びその調製方法

Country Status (8)

Country Link
US (2) US20130143923A1 (https=)
EP (1) EP2580205A1 (https=)
JP (1) JP2013528206A (https=)
CN (1) CN103068812A (https=)
AU (1) AU2011263493B2 (https=)
CA (1) CA2801835A1 (https=)
NZ (1) NZ604011A (https=)
WO (1) WO2011154739A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021008507A (ja) * 2014-04-14 2021-01-28 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． イミド系タンパク質分解モジュレーター及び関連する使用方法
US12239711B2 (en) 2014-04-14 2025-03-04 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102924432A (zh) * 2012-11-09 2013-02-13 常州制药厂有限公司 一种高纯度沙利度胺的制备方法
CN105473558B (zh) * 2013-06-20 2019-04-19 拜耳作物科学股份公司 作为杀螨剂和杀昆虫剂的芳基硫化物衍生物和芳基硫氧化物衍生物
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
CN104710411B (zh) * 2015-03-13 2017-04-26 安润医药科技（苏州）有限公司 阿伐那非的合成方法
CN110498788B (zh) * 2018-05-16 2021-09-17 欣凯医药化工中间体（上海）有限公司 一种高纯度沙利度胺α晶型的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005343895A (ja) * 2004-06-01 2005-12-15 Antibioticos Spa サリドマイドの製造方法
WO2008035378A2 (en) * 2006-09-20 2008-03-27 Matrix Laboratories Ltd An improved process for the preparation of thalidomide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB768821A (en) 1954-05-17 1957-02-20 Gruenenthal Chemie Novel products of the amino-piperidine-2, 6-dione series
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
CN1164586C (zh) 2002-10-28 2004-09-01 中国科学院长春应用化学研究所 沙利度胺及其衍生物的制备方法
US20050182097A1 (en) * 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
WO2009083724A1 (en) 2007-12-27 2009-07-09 Cipla Limited Processes for the preparation of thalidomide
CN102260241A (zh) * 2010-05-26 2011-11-30 重庆医药工业研究院有限责任公司 一种沙利度胺α晶型的工业化制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005343895A (ja) * 2004-06-01 2005-12-15 Antibioticos Spa サリドマイドの製造方法
WO2008035378A2 (en) * 2006-09-20 2008-03-27 Matrix Laboratories Ltd An improved process for the preparation of thalidomide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CARINI J P ET AL.: "Investigacao Preliminar Avaliando a Influencia dos Processos de Compactacao e Trituracao em Relacao", LATIN AMERICAN JOURNAL OF PHARMACY, vol. 28 (2), JPN6015025894, 2009, pages 226 - 233, ISSN: 0003104006 *
CARINI J P ET AL.: "Solid state evaluation of some thalidomide raw materials", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 372 (1-2), JPN6015025897, 2009, pages 17 - 23, ISSN: 0003104005 *
REEPMEYER J C ET AL.: "Characterization and crystal structure of two polymorphic forms of racemic thalidomide", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 2, JPN6015025896, 1994, pages 2063 - 2067, XP008140649, ISSN: 0003104007, DOI: 10.1039/P29940002063 *
平山令明, 有機化合物結晶作製ハンドブック, JPN6014022315, 2008, pages 10 - 11, ISSN: 0003104008 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021008507A (ja) * 2014-04-14 2021-01-28 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． イミド系タンパク質分解モジュレーター及び関連する使用方法
JP7169327B2 (ja) 2014-04-14 2022-11-10 アルビナス・オペレーションズ・インコーポレイテッド イミド系タンパク質分解モジュレーター及び関連する使用方法
JP2022191517A (ja) * 2014-04-14 2022-12-27 アルビナス・オペレーションズ・インコーポレイテッド イミド系タンパク質分解モジュレーター及び関連する使用方法
US12239711B2 (en) 2014-04-14 2025-03-04 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same

Also Published As

Publication number Publication date
CA2801835A1 (en) 2012-12-15
AU2011263493A8 (en) 2013-02-21
AU2011263493B2 (en) 2015-08-06
US20150218126A1 (en) 2015-08-06
WO2011154739A1 (en) 2011-12-15
AU2011263493A1 (en) 2013-01-10
US20130143923A1 (en) 2013-06-06
CN103068812A (zh) 2013-04-24
EP2580205A1 (en) 2013-04-17
NZ604011A (en) 2015-04-24

Similar Documents

Publication Publication Date Title
CN113993853B (zh) 氯苯唑酸及其盐的固态形式
US20150218126A1 (en) Crystalline forms of thalidomide and processes for their preparation
JP2007302658A (ja) イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
CN101939303B (zh) 波生坦的晶型
KR102715956B1 (ko) 리보시클립 염 및 이의 고상 형태
KR20040077872A (ko) 카베디롤의 결정질 고체 및 그 제조 방법
JP2009514988A (ja) イマチニブ塩基及びイマチニブメシレート、及びそれらの調製方法
CN102272118A (zh) 来那度胺的晶型及其制备方法
JP2007526251A (ja) エゼチミベ多形体
WO2023064519A1 (en) Solid state forms of elacestrant and processes for preparation thereof
JP7283832B2 (ja) ピリジンスルホンアミドリン酸エステル系化合物又はその医薬上許容される塩、その製造方法、その用途及び薬物組成物
WO2020014406A1 (en) Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl
JP2008539278A (ja) 結晶性ロスバスタチンカルシウム
CN101772491A (zh) 基本不含有二聚体杂质的瑞格列奈
JP5683276B2 (ja) ボセンタンの製造方法
JP2005523874A (ja) Ｎ−〔３−（３−シアノピラゾロ〔１，５−ａ〕ピリミジン−７−イル）フェニル〕−Ｎ−エチルアセタミド（ザレプロン）の精製方法、及び当該方法により得られうるザレプロンの結晶型
CN101160281A (zh) 结晶形态的普瑞巴林
KR20070072588A (ko) 텔미사르탄 나트륨의 비정질형 및 다형
WO2020168144A1 (en) Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(lh)- isoquinolinyl)ethyl] phenyl }-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl] -4- oxo-4h-chromene-2-carboxamide and of its mesylate salt
WO2019175722A1 (en) Process for the preparation of stable and highly pure crystalline form 2 of bilastine
WO2020198429A1 (en) Solid state forms of acalabrutinib
WO2013166966A1 (zh) 含氟的氘代ω-二苯基脲或其盐的多晶型物
WO2023222946A1 (en) Process for the preparation of cabozantinib
EP4665732A1 (en) Salts and solid forms of elenestinib
KR20070088507A (ko) 카베딜올의 결정질 형태 및 이것의 제조 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160531